1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Sanofi-Aventis: PharmaVitae Profile: New research report available at Fast Market Research

Recently published research from Datamonitor, "Sanofi-Aventis: PharmaVitae Profile", is now available at Fast Market Research

 
PRLog - May 19, 2011 - Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Sanofi-Aventis's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Sanofi-Aventis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158610_sanofiaventis_pharmavit...
------------------------------------------------------------

* Benchmark Sanofi-Aventis's performance against key rivals in the prescription pharmaceutical sector.* Analyse the positioning of the company as a diversified healthcare player with an enhanced focus on the vaccine, generic and consumer markets.* Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth.


Report Table of Contents:

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-
Financial performance, 2003-
Sanofi-Aventis: PharmaVitae forecasts at a glance
Strategic insight
Diversification will struggle to address near-term impact of generic exposure
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY UPDATE
Latest quarterly sales
Latest quarterly financial analysis
Q3
Q2
Latest comment
Q4
Q1
Q4
Q3
Q2
Latest prescription pharma product news
Q4
Q3
Q2
Q1
Q4
Latest corporate news
Q4
Q3
Q2
Q1
Q4
Future product milestones
COMPANY INTRODUCTION
Key findings
M&A history
Sanofi-SynthElabo: established in
Aventis: result of Hoechst and Rhone-Poulenc merger
Sanofi-Aventis: merged in
Subsequent M&A promotes diversified business model
M&A strategy
a) Dilution of exposure to patent expiry risk across blockbuster portfolio
b) Establish a diversified business model
c) Creation of industry-leading player in the global thrombosis market
d) Expansion of geographic presence
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-
Product analysis
Product analysis, 2003-
Product analysis, 2009-
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Generics analysis, 2009-
Launch/core/expiry configuration, 2009-
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-
Operating costs and profit analysis
Operating costs and profit analysis, 2003-
Operating cost ratio and profit margin analysis, 2003-
Operating cost ratio and profit margin analysis, 2009-
Operating costs and profit analysis, 2009-
KEY PRODUCTS
Key findings
Overview
Lantus
Vaccines
aflibercept
Lovenox
Plavix
Aprovel/CoAprovel
Taxotere
Eloxatine
APPENDIX
References
Abbreviations
Exchange rates

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical, Research, Biotech
Tags:prescription, sanofi-aventis, pharmaceutical, pharmavitae, diversified, generic, pharma, taxotere, exposure, vaccine
Shortcut:prlog.org/11498549
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share